REFERENCES
1. Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab.
2007;21(4):517-33.
2. Hong SM, Park CY, Hwang DM, Han KA, Lee CB, Chung CH, et al. Efficacy
and safety of adding evogliptin versus sitagliptin for metformin-treated
patients with type 2 diabetes: A 24-week randomized, controlled trial
with open label extension. Diabetes Obes Metab. 2017;19(5):654-63.
3. Park J, Park SW, Yoon KH, Kim SR, Ahn KJ, Lee JH, et al. Efficacy and
safety of evogliptin monotherapy in patients with type 2 diabetes and
moderately elevated glycated haemoglobin levels after diet and exercise.
Diabetes, Obesity and Metabolism. 2017;19(12):1681-7.
4. Gu N, Park MK, Kim TE, Bahng MY, Lim KS, Cho SH, et al. Multiple-dose
pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel
dipeptidyl peptidase IV inhibitor, in healthy volunteers. Drug Des Devel
Ther. 2014;8:1709-21.
5. Kim HJ, Kwak WY, Min JP, Lee JY, Yoon TH, Kim HD, et al. Discovery of
DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the
treatment of type 2 diabetes. Bioorganic & medicinal chemistry letters.
2011;21(12):3809-12.
6. Oh E, Choi C, Kim C, Kim K, Kim Y, Kim S, et al. Effects of
clarithromycin on the pharmacokinetics of evogliptin in healthy
volunteers. Journal of clinical pharmacy and therapeutics.
2017;42(6):689-94.
7. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon K-H, et al.
Diabetes in Asia: epidemiology, risk factors, and pathophysiology. Jama.
2009;301(20):2129-40.
8. Heather D. Langtry, Balfour JA. Glimepiride. Drugs.
1998;55(4):563-87.
9. Hotta N. A new perspective on the biguanide, metformin therapy in
type 2 diabetes and lactic acidosis. Journal of diabetes investigation.
2019.
10. Ko S-H, Hur K-Y, Rhee SY, Kim N-H, Moon MK, Park S-O, et al.
Antihyperglycemic agent therapy for adult patients with type 2 diabetes
mellitus 2017: a position statement of the Korean Diabetes Association.
Diabetes & metabolism journal. 2017;41(5):337-48.
11. McGuire H, Longson D, Adler A, Farmer A, Lewin I. Management of type
2 diabetes in adults: summary of updated NICE guidance. Bmj.
2016;353:i1575.
12. Serra D, He Y, Bullock J, Riviere G, Balez S, Schwartz S, et al.
Evaluation of pharmacokinetic and pharmacodynamic interaction between
the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and
pioglitazone in patients with Type 2 diabetes. International journal of
clinical pharmacology and therapeutics. 2008;46(7):349-64.
13. Friedrich C, Metzmann K, Rose P, Mattheus M, Pinnetti S, Woerle HJ.
A randomized, open-label, crossover study to evaluate the
pharmacokinetics of empagliflozin and linagliptin after coadministration
in healthy male volunteers. Clinical therapeutics. 2013;35(1):A33-A42.
14. Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivistö KT.
Effects of fluconazole and fluvoxamine on the pharmacokinetics and
pharmacodynamics of glimepiride. Clinical Pharmacology & Therapeutics.
2001;69(4):194-200.
15. Macha S, Mattheus M, Pinnetti S, Seman L, Woerle HJ.
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2
inhibitor, and glimepiride following co-administration in healthy
volunteers: a randomised, open-label, crossover study. Journal of
Diabetes Research and Clinical Metabolism. 2012;1(1):14.
16. Tripathi AS, Timiri AK, Mazumder PM, Chandewar A. Does glimepiride
alter the pharmacokinetics of sildenafil citrate in diabetic nephropathy
animals: investigating mechanism of interaction by molecular modeling
studies. Journal of molecular modeling. 2015;21(10):276.
17. Ryan AS, Egan JM, Habener JF, Elahi D. Insulinotropic hormone
glucagon-like peptide-1-(7–37) appears not to augment insulin-mediated
glucose uptake in young men during euglycemia. The Journal of Clinical
Endocrinology & Metabolism. 1998;83(7):2399-404.
18. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide]
but not of synthetic human gastric inhibitory polypeptide in patients
with type-2 diabetes mellitus. The Journal of clinical investigation.
1993;91(1):301-7.
19. Holst JJ, Gromada J. Role of incretin hormones in the regulation of
insulin secretion in diabetic and nondiabetic humans. American Journal
of Physiology-Endocrinology And Metabolism. 2004;287(2):E199-E206.
20. Jung CH, Park CY, Ahn KJ, Kim NH, Jang HC, Lee MK, et al. A
randomized, double-blind, placebo-controlled, phase II clinical trial to
investigate the efficacy and safety of oral DA-1229 in patients with
type 2 diabetes mellitus who have inadequate glycaemic control with diet
and exercise. Diabetes Metab Res Rev. 2015;31(3):295-306.
21. Rhee SJ, Choi Y, Lee S, Oh J, Kim SJ, Yoon SH, et al.
Pharmacokinetic and pharmacodynamic interactions between metformin and a
novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects.
Drug Des Devel Ther. 2016;10:2525-34.
22. Dunning B, Foley J, Ahrén B. Alpha cell function in health and
disease: influence of glucagon-like peptide-1. Diabetologia.
2005;48(9):1700-13.